Screener
Castle Biosciences CSTL Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Net gains (losses) on equity securities | 2,022 | (1,425) |
| Interest expense | (134) | (17) |
| Other loss | (439) | — |
| Loss before income taxes | (14,413) | (26,271) |
| Income tax expense (benefit) | 109 | (423) |
| Net loss | $(14,522) | $(25,848) |
| Loss per share, basic and diluted | $(0.49) | $(0.90) |
| Weighted-average shares outstanding, basic and diluted | 29,889 | 28,609 |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's business segments — net loss?
- Castle Biosciences (CSTL) reported business segments — net loss of -$14.52M in Q1 2026.
- How has Castle Biosciences's business segments — net loss changed year-over-year?
- Castle Biosciences's business segments — net loss increased by 43.8% year-over-year, from -$25.85M to -$14.52M.
- What is the long-term trend for Castle Biosciences's business segments — net loss?
- Over 3 years (2022 to 2025), Castle Biosciences's business segments — net loss has grown at a -28.9% compound annual growth rate (CAGR), from -$67.14M to -$24.16M.
- What does business segments — net loss mean?
- Indicates the bottom-line financial result of the segment after deducting all associated operating expenses from revenues. A negative value signifies that the segment's costs currently exceed its revenue generation, highlighting the need for operational leverage.
Ask your AI about Castle Biosciences's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude